{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:50:28Z","timestamp":1781913028070,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP110172"],"award-info":[{"award-number":["RP110172"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["7001-14"],"award-info":[{"award-number":["7001-14"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011034","name":"Sidney Kimmel Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA094237"],"award-info":[{"award-number":["P01 CA094237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA126752"],"award-info":[{"award-number":["P50 CA126752"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jcyt.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T20:12:31Z","timestamp":1541189551000},"page":"212-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy"],"prefix":"10.1016","volume":"21","author":[{"given":"MAMTA","family":"KALRA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ULRIKE","family":"GERDEMANN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JESSICA D.","family":"LUU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MINTHRAN C.","family":"NGO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANN M.","family":"LEEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRYSTAL U.","family":"LOUIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CLIONA M.","family":"ROONEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"STEPHEN","family":"GOTTSCHALK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jcyt.2018.08.001_bib0001","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2018.08.001_bib0002","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J. Immunother."},{"issue":"8","key":"10.1016\/j.jcyt.2018.08.001_bib0003","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.jcyt.2018.08.001_bib0004","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcyt.2018.08.001_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jcyt.2018.08.001_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","article-title":"Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jcyt.2018.08.001_bib0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcyt.2018.08.001_bib0008","first-page":"1898","article-title":"Fields Virology","author":"Longnecker","year":"2013"},{"issue":"19","key":"10.1016\/j.jcyt.2018.08.001_bib0009","first-page":"5584","article-title":"Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies","volume":"60","author":"Decaussin","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jcyt.2018.08.001_bib0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4143\/crt.2011.43.4.250","article-title":"Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers","volume":"43","author":"Jang","year":"2011","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jcyt.2018.08.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-5-70","article-title":"Secretion of Epstein-Barr virus-encoded BARF1 oncoprotein from latently infected B cells","volume":"5","author":"Fiorini","year":"2008","journal-title":"Virol J"},{"key":"10.1016\/j.jcyt.2018.08.001_bib0012","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of Nasopharyngeal Carcinoma with Epstein-Barr Virus-specific T Lymphocytes","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2018.08.001_bib0013","first-page":"325","article-title":"T-Cell Responses to EBV","volume":"391","author":"Hislop","year":"2015","journal-title":"Current topics in microbiology and immunology"},{"issue":"5","key":"10.1016\/j.jcyt.2018.08.001_bib0014","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ijc.23621","article-title":"Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy","volume":"123","author":"Martorelli","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.jcyt.2018.08.001_bib0015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2326-6066.CIR-15-0108","article-title":"Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy","volume":"4","author":"Fae","year":"2016","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.jcyt.2018.08.001_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annual review of immunology"},{"issue":"2","key":"10.1016\/j.jcyt.2018.08.001_bib0017","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2011.12.007","article-title":"Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis","volume":"22","author":"Takada","year":"2012","journal-title":"Seminars in cancer biology"},{"issue":"1","key":"10.1016\/j.jcyt.2018.08.001_bib0018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12038-015-9502-z","article-title":"BARF1 gene silencing triggers caspase-dependent mitochondrial apoptosis in Epstein-Barr virus-positive malignant cells","volume":"40","author":"Mohidin","year":"2015","journal-title":"J Biosci"},{"issue":"12","key":"10.1016\/j.jcyt.2018.08.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003095","article-title":"An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection","volume":"8","author":"Ohashi","year":"2012","journal-title":"PLoS pathogens"},{"issue":"6","key":"10.1016\/j.jcyt.2018.08.001_bib0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/rmv.1758","article-title":"BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator","volume":"23","author":"Hoebe","year":"2013","journal-title":"Reviews in medical virology"},{"issue":"3","key":"10.1016\/j.jcyt.2018.08.001_bib0021","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.V97.3.708","article-title":"Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T\/NK-cell lymphomas associated with the Epstein-Barr virus","volume":"97","author":"Nagata","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2018.08.001_bib0022","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1365-2141.2003.04359.x","article-title":"Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T\/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions","volume":"121","author":"Zhang","year":"2003","journal-title":"British journal of haematology"},{"issue":"5","key":"10.1016\/j.jcyt.2018.08.001_bib0023","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2018.08.001_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CJI.0000000000000014","article-title":"Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity","volume":"37","author":"Ngo","year":"2014","journal-title":"J. Immunother."},{"issue":"12","key":"10.1016\/j.jcyt.2018.08.001_bib0025","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jcyt.2018.08.001_bib0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jmv.20327","article-title":"Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression","volume":"76","author":"Seto","year":"2005","journal-title":"Journal of medical virology"},{"issue":"11","key":"10.1016\/j.jcyt.2018.08.001_bib0027","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2008-05-157222","article-title":"Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients","volume":"113","author":"Louis","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jcyt.2018.08.001_bib0028","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2018.08.001_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jcyt.2018.08.001_bib0030","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"European journal of immunology"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918305620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324918305620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:36:29Z","timestamp":1761442589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324918305620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1465324918305620"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.08.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}